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Abstract
Background: Early treatment responses are important prognostic factors in childhood T-cell acute lymphoblastic
leukemia (T-ALL) patients. The predictive values of early treatment responses in Chinese childhood T-ALL patients
were still unknown.
Methods: From January 2003 to December 2012, 74 consecutive patients aged ≤15 years with newly diagnosed T-ALL
were treated with BCH-2003 protocol or CCLG-2008 protocol in the Department of Pediatric, Institute of Hematology
and Blood Diseases Hospital in China. Predictive values of early treatment responses, including prednisone response,
bone marrow morphology at day 15 and day 33 during induction chemotherapy, and minimal residual disease (MRD)
monitored by flow cytometry after induction therapy (time point 1, TP1) and before consolidation therapy (time point
2, TP2), were analyzed.
Results: The 5-year event free survival (EFS) and overall survival (OS) rates for these patients were 62.5 % (SE, 6.4) and
62.7 % (SE, 6.6), respectively. Prednisone poor responder was strongly associated with increased chance of induction
failure (14.8 %) and decreased survival rate (5 year EFS rate, 51.1 % (SE, 10.5)). Patients with ≥25 % blast cells in bone
marrow at day 15 were more likely to have an inferior outcome. 93.2 % of the T-ALL patients achieved complete
remission at day 33 while patients with resistant disease all died of disease progression. MRD ≥10−2 at TP1 or
MRD ≥10−3 at TP2 was significantly related to dismal prognosis. Risk groups classified by MRD at two time points
could stratify patients into different groups: 29.0 % of the patients were MRD standard risk (MRD < 10−4 at both
time points) with 3-year EFS rate of 100 %, 29.0 % were MRD high risk (MRD ≥10−2 at TP1 or MRD ≥10−2 at TP2)
with 3-year EFS rate of 55.6 % (SE, 16.6) , and the rest of patients were defined as MRD intermediate risk with 3-year EFS
rate of 85.7 % (SE, 13.2).
Conclusion: Our study demonstrated that MRD was the most powerful predictor of treatment outcome in childhood
T-ALL patients and conventional morphological assessments of treatment response still played important roles in
predicting treatment outcome and tailoring treatment intensity especially in countries with inadequate skills or
financial resources for MRD monitoring.
Keywords: Childhood, T-cell acute lymphoblastic leukemia, Prednisone response, Minimal residual disease,
Prognosis
* Correspondence: xfzhu1981@126.com
Department of Pediatric, Institute of Hematology and Blood Diseases
Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 288 Nanjing Road, Tianjin 300020, Peoples Republic of China
© 2015 Wei et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wei et al. BMC Pediatrics  (2015) 15:80 
DOI 10.1186/s12887-015-0390-z
Background
Acute lymphoblastic leukemia (ALL) with T-cell immuno-
phenotype accounting for approximately 15 % of the child-
hood ALL patients was considered to be unfavorable until
more intensive chemotherapy had be applied in the last
two decades [1–6]. Childhood T-cell acute lymphoblastic
leukemia (T-ALL) patients are more likely to be male,
older than 9 years and present with high white blood cell
(WBC) count, mediastinal mass and central nervous sys-
tem leukemia [1, 2, 6].
Early in vivo responses are known to be powerful pre-
dictors of treatment outcome in childhood ALL [7–11].
Prednisone response (PR) was found to be related to
treatment outcome by the Berlin-Frankfurt-Munster
(BFM) study in 1983 [7] and since then the predictive
value of PR was confirmed in many studies [12–15]. T-
ALL patients are more likely to have a worse steroid re-
sponse than B-ALL patients [8, 10, 16]. Bone marrow
morphology at day 15 during induction therapy is a well-
established predictive factor and patients with ≥25 % blast
cells in bone marrow usually have an inferior survival
[9, 13, 17, 18]. During the last two decades, minimal re-
sidual disease (MRD) in childhood ALL had been
proved to be a remarkable predictive factor and already
become an integral part of risk stratifications in many
long established leukemia groups [19–24]. The most
widely applicable MRD technique is polymerase chain
reaction (PCR) analysis of T-cell receptor (TCR) and
clone-specific immunoglobulin gene arrangements [25–27].
Although less standardized than molecular detection of
MRD, flow cytometry (FCM) is faster, cheaper and
more applicable [18, 22, 28–31]. Patients’ prognosis
and quality of life were further improved by individual-
ized treatment. The majority of MRD studies were based
on B-ALL, whereas MRD studies in T-ALL were scarce. A
slower clearance of leukemia cells was found in T-ALL pa-
tients and MRD risk group classified by MRD levels at the
end of induction and before consolidation therapy was
identified to be the most powerful independent prognostic
factor in T-ALL patients [32, 33].
In this study, the clinical features and early treatment
responses of Chinese pediatric T-ALL patients were
summarized. The predictive values of early treatment
responses, including prednisone response, bone marrow
morphology at day 15 and day 33 during induction
therapy, MRD levels after induction and before consoli-
dation therapy, and their correlations were analyzed.
Prednisone response, bone marrow morphology at day
33, and MRD were identified to be powerful prognostic
factors in our T-ALL patients. This is the first time that
the predictive values of early treatment responses espe-
cially MRD levels were explored in Chinese pediatric T-
ALL patients.
Methods
Patients and treatment protocols
From January 2003 to December 2012, 74 consecutive
patients aged 15 years or younger with newly diagnosed
T-ALL were enrolled in the Department of Pediatric, In-
stitute of Hematology and Blood Diseases Hospital, Peking
Union Medical College. The diagnosis of ALL was based
on morphologic, cytochemical, and immunophenotypic
criteria. T-cell lineage was established based on the
European Group for the Immunological Characterization
of Leukemias criteria (EGIL). 27 patients and 47 patients
were treated with BCH-2003 protocol (used between
January 2003 and March 2008) and CCLG-2008 protocol
(used after April 2008), respectively. Patients were
stratified into intermediate risk (IR) and high risk (HR)
groups according to cytogenetic aberration, prednisone
response, bone marrow morphology at day 15 and 33,
and MRD levels (The details of stratification criteria
and treatment protocols were described in Additional
file 1: Table S1, S2, S3). One patient treated with BCG-
2003 and one treated with CCLG-2008 protocol re-
ceived allogeneic hematopoietic stem cell transplantation
(allo-HSCT). Written informed consent from the parents
or guardians of the study participants were obtained in ac-
cordance to the Declaration of Helsinki before initiation
of treatments, and the protocols were approved by the
ethics committee of Institute of Hematology and Blood
Diseases Hospital.
Flow cytometric assessment of minimal residual disease
MRD was included to stratify risk group in CCLG-2008
protocol. Thus, MRD levels were monitored in patients
treated with CCLG-2008 protocol. Bone marrow aspirates
were collected in preservative-free heparin at the end of
remission induction (on day 33) and before consolidation
therapy (in week 12). Leukemia-associated immunophe-
notypes were determined by multivariable flow cytometry
and multiple marker combinations (CD7/CD45/CD33/
CD34/CD117/CD10/CD2/cCD3/TDT and CD7/CD45/
CD3/CD4/CD8/CD99/CD5/CD16/CD56) were performed
in the Department of Pathology in our hospital.
Early response and relapse criteria
Prednisone response (PR) was defined by the absolute
number of leukemia blasts in the peripheral blood after
seven days of prednisone treatment and one intrathecal
(IT) dose of methotrexate. The number of peripheral
blasts of prednisone good responder (PGR) was <1000/
ul, whereas the value of prednisone poor responder
(PPR) was ≥1000/ul. BM morphology was evaluated at
day 15 during induction therapy and BM statuses were
defined as M1 (lymphoblasts < 5 %), M2 (≥5 % and <25 %)
and M3 (≥25 %). Complete remission (CR) was defined as
normal BM cellularity with <5 % undifferentiated cells at
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day 33 of induction therapy, absence of leukemia blasts in
peripheral blood and CSF, and no extramedullary infiltra-
tion. MRD were assessed at the end of induction treat-
ment (day 33, time point 1, TP1) and in week 12 before
consolidation therapy (time point 2, TP2) by flow cytome-
try. Relapse was defined as recurrence of ≥25 % lympho-
blasts in bone marrow or local leukemia infiltration sites.
Statistics
December 31, 2012 was chosen as the reference date for
collection of data. Chi-square test was used for compari-
son of binary variables, and Mann–Whitney U test was
used for comparison of continuous variables. Outcome
events were induction failure, induction death, relapse,
death during remission, and secondary malignancy.
Event free survival (EFS) was defined as the time from
diagnosis to the date of last follow in CR or first event.
Induction failure or induction death were considered to
be event at time zero. Overall survival (OS) was mea-
sured from the date of diagnosis to the time of death
from any cause. Patients lost to follow up were censored
at the time of their withdrawal. Distributions of EFS and
OS rates were estimated by the Kaplan-Meier method
[34] and differences were compared with two-sided log
rank test [35]. The Cox proportional-hazards model was
used for multivariate analyses of prognostic factors [36].
Estimated hazard ratios were reported as relative risks
with 95 % confidence intervals. All P values were two-
sided and P < 0.05 was considered statistically significant.




Presenting clinical features of the 74 T-ALL patients and
the outcomes associated with clinical characteristics
were summarized in Table 1. 57 (77.0 %) patients were
male and 17 (33.0 %) patients were female. Ages ranged
from 1 to 15 years with a median age of 9 years. 45
(60.8 %) patients presented with initial white blood cell
(WBC) count ≥100 × 109/L. 29 (40.3 %) patients were
classified as the intermediate risk (IR) group and 43
(59.7 %) patients were in the high risk (HR) group ac-
cording to the risk stratifications. 27 (36.5 %) patients
followed BCH-2003 protocol and 47 (63.5 %) were
treated with CCLG-2008 protocol. The median follow-
up time of the two protocols were 73 and 19 months, re-
spectively. There were no significant differences in the
distributions of age, sex, leukocyte count, risk group,
karyotype and early treatment responses between BCH-
2003 protocol and CCLG-2008 protocol, but patients
with CNS3 status were more in BCH-2003 protocol and
more patients with mediastinal mass were found in
CCLG-2008 protocol (Additional file 1: Table S4).
Treatment outcome
The 5-year EFS and OS rates for all patients were 62.5 %
(SE, 6.4) and 62.7 % (SE, 6.6), respectively, with a me-
dian follow-up of 22 months (Fig. 1). Complete remis-
sion (CR) could be assessed in 72 patients on day 33 of
Table 1 Clinical characteristics and outcomes
Variables No. (%) 5-year EFS (SE) P value
Total 74 62.5 (6.4)
Treatment protocol
BCH-2003 27 (36.5) 61.7 (10.8) 0.274
CCLG-2008 47 (63.5) 55.6 (9.6)
Gender
Male 57 (77.0) 60.7 (7.1) 0.461
Female 17 (33.0) 65.9 (16.5)
Age (years)
1-10 43 (58.1) 55.8 (8.8) 0.47
≥10 31 (41.9) 73.9 (8.0)
Initial WBC (×109/L)
<100 29 (39.2) 68.2 (11.6) 0.076
≥100 45 (60.8) 58.0 (7.8)
CNS involvement
CNS1/2 68 (91.9) 64.9 (6.7) 0.034
CNS3 6 (8.1) 33.3 (19.2)
Mediastinal mass
Present 28 (40.6) 68.8 (9.6) 0.805
Absent 41 (59.4) 59.7 (8.3)
Not known 5
MLL rearrangement
Present 3 (6.1) 100.0 0.217
Absent 46 (93.9) 57.0 (10.6)
Not known 25
karyotype
Normal 31 (56.4) 67.5 (9.2) 0.163
Structure abnormal 17 (30.9) 82.4 (9.2)
Numerical abnormal 7 (12.7) 28.6 (22.3)
Failure or Missing 19
Risk group
IR 29 (40.3) 79.0 (10.3) 0.009
HR 43 (59.7) 54.8 (8.2)
Not known 2
SIL-TAL1 translocation 3-year EFS (SE)
Present 8 (19.0) 100.0 0.102
Absent 34 (81.0) 51.7 (12.3)
Not known 32
WBC White blood cell; IR Intermediate risk; HR High risk; SE Standard error; CNS
Central nervous system
By Kaplan-Meier method
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Fig. 1 a Event-free survival (EFS) rates and b Overall survival (OS) rates for all the patients and patients classified by treatment protocols (BCH-
2003 protocol or CCLG-2008 protocol )
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induction therapy. 69 (93.2 %) patients achieved CR and
5 patients failed. Of the 5 patients, 3 patients suffered in-
duction resistance and 2 died during induction chemo-
therapy. None of the patients with induction resistance
achieved CR after the intensified re-induction therapy
and all of them died of disease progression. 15 (20.3 %)
patients relapsed in bone marrow isolated (n = 11) or
combined CNS (n = 4) or testis (1 patients relapsed at
BM combined both CNS and testis). 10 (66.7 %) patients
relapsed within 18 months and the others relapsed be-
tween 18 months and 36 months. Other events were in-
duction failure (n = 3), induction death (n = 2), and death
in remission (n = 4).
The 5-year EFS rates for patients treated with BCH-
2003 and CCLG-2008 protocols were 55.6 % (SE, 9.6)
and 61.7 % (SE, 10.8), respectively (P = 0.274), and the 5-
year OS rates were 55.6 % (SE, 9.6) and 63.6 % (SE,
11.0), respectively (P = 0.283) (Fig. 1). 6 patients had cen-
tral nervous system (CNS) involvement at the time of
diagnosis and their 5-year EFS rate was much lower than
that of the patients who were CNS1 or CNS2 status,
33.3 % (SE, 19.2) and 64.9 % (SE, 6.7), respectively (P =
0.034). The 5-year EFS rates were significantly different
between the IR and HR groups (79.0 % (SE, 10.3) VS
54.8 % (SE, 8.2), respectively; P = 0.009). Patients who
had SIL-TAL1 translocation seemed to have a better
outcome with the 3-year EFS rate of 100 %, but without
significance due to the small number of patients (P =
0.102). As shown in Table 1, no significant differences
were observed in EFS rates based on: age at diagnosis
(P = 0.47), sex (P = 0.461), presence of mediastinal mass
(P = 0.85), MLL rearrangement (P = 0.217) or karyotype
(P = 0.163).
Prednisone response
Prednisone response could be evaluated in 61 patients.
Of those patients, 34 (55.7 %) patients were defined as
prednisone good responder (PGR), while 27 (44.3 %)
were classified as prednisone poor responder (PPR). The
relationships between PR and clinical features were ana-
lyzed and patients with initial WBC ≥ 100 × 109/L were
more likely to respond poorly to prednisone (P = 0.033,
Additional file 1: Table S5). PPR patients had a significant
lower 5-year EFS rate than PGR patients. The 5-year EFS
rate was 51.1 % (SE, 10.5) for PPR patients compared to
73.6 % (SE, 10.8) for PGR patients (P = 0.028, Fig. 2).
Bone marrow morphology at day 15
Bone marrow smears at day 15 of induction therapy
were eligible for evaluation in 65 patients. 36 (55.4 %)
patients were defined as M1 status, 19 (29.2 %) patients
were classified as M2 status and 10 (15.4 %) patients
Fig. 2 Kaplan-Meier estimate of event-free survival according to prednisone response in 61 T-ALL patients. PGR: prednisone good responder; PPR:
prednisone poor responder; SE, standard error
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were defined as M3 status. The 5-year EFS rates were
61.2 % (SE, 9.2), 73.7 % (SE, 13.7) and 50.0 % (SE, 15.8)
for the patients with M1, M2 and M3 status, respectively
(P = 0.129, Fig. 3a). M3 status at day 15 is internationally
recognized as a poor prognostic factor and there was no
difference in treatment outcome between M1 and M2
patients in our study. Thus, we combined M1 and M2
patients into one group to compare with M3 patients.
The 5-year EFS rate for M3 patients was lower than that
for M1/2 patients with borderline significance (50 % (SE,
15.8) VS 65.3 % (SE, 7.7), P = 0.073, Fig. 3b). The rela-
tionships between clinical features and BM status at day
15 were also analyzed and no significant correlation was
found (Additional file 1: Table S6).
MRD at day 33 and in week 12
33 and 32 patients were evaluable for MRD analysis at
day 33 (TP1) and in week 12 (TP2), respectively. All the
patients were treated with CCLG-2008 protocol. At first,
we explored the cutoff values of MRD levels at each time
point. Patients eligible for MRD analysis were divided into
subgroups according to their MRD levels at TP1 or TP2:
MRD < 10−4 and ≥10−4, MRD <10−3and ≥10−3, MRD <
10−2/≥10−2. Numbers of patients and their 3-year EFS
rates for these subgroups were assessed and showed in
Table 2. Patients with MRD ≥10−2 at any time point
had the worst outcome (3-year EFS rate of 33.3 % (SE,
27.2 %) at either time point). At TP2, patients could
also be classified into two groups by MRD level of 10−3.
23 (71.9 %) patients with MRD < 10−3 had an excellent
3-year EFS rate compared with patients with MRD ≥10−3 (
87.5 % (SE, 11.7) and 55.6 % (SE, 16.6), respectively).
According to the above analysis of MRD levels at TP1
and TP2, we subsequently stratified the patients into three
MRD risk groups: 9 ( 29.0 %) patients with MRD <10−4 at
both time points were defined as standard risk (MRD-SR);
9 (29.0 %) patients with MRD ≥10−2 at TP1 or ≥10−3 at
TP2 were at high risk group (MRD-HR) and 13 (42.0 %)
patients were defined as intermediate risk (MRD-IR)
group. These subgroups had distinct outcomes, with 3-
year EFS rates of 100 %, 85.7 % (SE, 13.2), and 55.6 % (SE,
16.6) for MRD-SR, MRD-IR, and MRD-HR, respectively
(P = 0.019, Fig. 4). The correlations between MRD risk
groups and clinical features were analyzed and no associ-
ation was observed (Additional file 1: Table S7).
Correlations of the early treatment responses
We further analyzed if prednisone response was also a
good predictor to other treatment responses. Morpho-
logical evaluation of bone marrow at day 15 was per-
formed in 59 of the 61 patients with PR results. In PGR
patients, only 3 (8.8 %) patients were defined as M3 sta-
tus while 7 (28.0 %) patients out of the 25 PPR patients
were M3 status (P = 0.019). All of the PGR patients
achieved CR while the CR rate of the PPR patients was
only 85.2 % (P = 0.034). 50 % of the PPR patients were in
MRD-HR group whereas the proportion of PGR patients
was only 16.7 % (P = 0.102). Thus, patients who responded
poorly to prednisone tended to be poor responders in the
late course of chemotherapy.
Age, WBC count, gender, CNS involvement, risk group,
prednisone response, bone marrow at day 15 and MRD risk
group were included in the multivariable analysis of event
free survival. Only MRD risk group was found to be the sig-
nificant independent prognostic factor (P = 0.032, RR = 11,
95 % CI, 1.2-100). The number of patients in the Cox re-
gression model was limited by patients eligible for MRD
risk group assessment, so if MRD risk group was omitted
form the model, PPR was significantly related to the hazard
of events (P = 0.044, RR = 2.79, 95%CI, 1.03-7.58).
Discussion
To our knowledge, this is the first study about early
treatment responses in Chinese pediatric T-ALL pa-
tients. Since last decade, the outcome of pediatric B-
ALL patients has been progressively improved in China,
with an overall 5-year EFS rate of approximately 85 %
[37]. However, the prognosis of T-ALL patients was still
not optimistic, with a 5-year EFS rate of around 65 %
[37]. In our study, the 5-year EFS and OS rates for the
T-ALL patients were 62.5 % (SE, 6.4) and 62.7 % (SE,
6.6), which were lower than that in western countries
[25, 26, 38–41]. Only two patients in HR group under-
went allo-HSCT and the rest patients in HR group were
just treated with chemotherapy because of financial rea-
son or without appropriate donors. Low percent of pa-
tients receiving bone marrow transplantation in HR
group compromised our treatment outcome. The major
event was relapse and most patients (66.7 %) relapsed
within 18 months from diagnosis. Almost all of the pa-
tients with relapse gave up due to limited financial re-
source or died of disease progression because of poor
treatment response. Abandonment after relapse was an-
other reason for low survival rate compared with other
studies. Thus, strategies should be made to decrease
abandonment and improve the outcome of patients with
relapse in China or other underdeveloped countries.
Like other pediatric T-ALL studies, the majority of our
patients were male and the median age was 9 years old
[1, 2, 6]. Patients with initial WBC count ≥100 × 109/L
accounted for 60.8 % and seemed to have a worse sur-
vival. More than half of the patients were in the HR
group with 5-year EFS rate of 54.8 % (SE, 8.2) whereas
the 5-year EFS rate for the IR group was much higher,
79.0 % (SE, 10.3). Of the presenting clinical features,
CNS leukemia was strongly associated with poor treat-
ment outcome. Thus, efforts to increase T-ALL survival
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Fig. 3 Kaplan-Meier estimate of event-free survival according to bone marrow morphology at day 15 during induction chemotherapy in 65 T-ALL
patients. a Patients classified into three groups: M1 (bone marrow blast <5 %), M2 (bone marrow blast 5 % and <25 %), and M3 (bone marrow
blast ≥25 %). b Patients classified into two groups: M1 +M2 (bone marrow blast <25 %) and M3 (bone marrow blast ≥25 %). SE, standard error
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should be focused on patients in HR group or with CNS
leukemia in our future study.
Prednisone response has consistently been found to be
one of the most powerful independent prognostic factors
in many studies [7, 12–15] and T-ALL patients are more
likely to be PPR [10, 16]. 55.7 % of our T-ALL patients
were classified as PPR while the percent was only 5-15 %
in B-ALL patients [8, 10, 16]. Patients with initial WBC
≥100 × 109/L were at high risk of PPR (P = 0.033) in our
study. We proved that the prognosis of PPR patients was
inferior to that of the corresponding PGR patients in
Chinese pediatric T-ALL patients. We further explored
the correlations of PR with other treatment responses. If
patients responded poorly to prednisone, they were
more likely to be defined as M3 bone marrow status at
day 15, underwent induction failure at day 33 and fell
into the MRD-HR group than PGR patients. Thus, pred-
nisone response is a robust predictor, inexpensive and
convenient tool to predict treatment outcome and adapt
treatment intensity, especially in underdeveloped coun-
tries with inadequate skills and resources for MRD
monitoring.
For more than two decades, cytomorphological re-
sponses of bone marrow have been the leading strategies
for risk classification [10, 13, 17, 18]. In our study, we
analyzed bone marrow morphologies at day 15 and day
Table 2 Distribution of MRD levels at two time points and comparison of event-free survival in patients classified by MRD levels
Time point MRD cut-off N (%) of patients 3-year EFS (%, SE) Long-rank test
values
Time point 1 <10−4/≥10−4 16 (48.5)/17 (51.5) 80 (17.9)/73.2 (11.9) P = 0.337
<10−3/≥10−3 27 (81.8)/6 (18.2) 77.2 (12.7)/66.7 (19.2) P = 0.243
<10−2/≥10−2 30 (90.9)/3 (9.1) 80.8 (10.8)/33.3 (27.2) P = 0.006
Time point 2 <10−4/≥10−4 14 (43.8)/18 (56.2) 100/69.1 (11.9) P = 0.059
<10−3/≥10−3 23 (71.9)/9 (28.1) 87.5 (11.7)/55.6 (16.6) P = 0.004
<10−2/≥10−2 29 (90.6)/3 (9.4) 83.8 (9.8)/33.3 (27.2) P = 0.002
SE Standard error
Fig. 4 Kaplan-Meier estimate of event-free survival according to minimal residual disease (MRD) risk groups. Patients with MRD < 10−4 at TP1 and
TP2 were stratified as the standard-risk group (MRD-SR); MRD≥ 10−2 at TP1 or MRD≥ 10−3 at TP2 as high-risk group (MRD-HR); the rest as the
intermediate risk group (MRD-IR)
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33 of induction therapy. At day 15, patients with M3 sta-
tus had a worse outcome than M1/M2 patients with
borderline significance (P = 0.073). The CR rate of the
patients evaluated on day 33 was 93.2 % and equal to
other western studies [37–40]. Patients with induction
resistance all died of disease progression making induc-
tion failure the worst predictive factor in all of the early
treatment response indicators.
MRD is widely applied in contemporary childhood
ALL studies. In the AIEOP-BFM-ALL 2000 study, as-
sessments of MRD at day 33 and day 78 based on im-
munoglobulin and TCR gene rearrangements were
introduced for risk stratification [33]. In our study, MRD
levels measured by FCM at day 33 and in week 12 were
incorporated in risk-classification algorithms and used to
adapt therapy in CCLG-2008 protocol. Thus, the num-
bers of patients with MRD data decreased to 33 at TP1,
32 at TP2 and 31 at both time points. Then we wanted
to find out the cut-off values of MRD levels at TP1 and
TP2. MRD levels ≥10−2 were found to be related to poor
prognosis at both time points especially at day 33. In
week 12, MRD at the level of 10−3 was considered more
appropriate than 10−2 as it could identify more patients
with dismal prognosis. According to our MRD cut-off
levels, we stratified our patients into three MRD risk
groups: 29.0 % of the patients were MRD-SR ( MRD < 10
−4 at both time points), 29.0 % were MRD-HR (MRD
≥10−2 at TP1 or ≥10−3 at TP2) and 42.0 % were MRD-
IR. This constitution of MRD risk groups was similar to
previous MRD study in T-ALL patients [33]. The MRD-
HR group displayed a remarkable worse outcome than
the MRD-SR and MRD-IR groups. Cox regression ana-
lysis also showed that MRD-HR patients had a signifi-
cant 11-fold increase of events compared with MRD-SR
and MRD-IR patients. The reliability of our MRD ana-
lysis might be weakened by small number of patients.
However, our study could still provide us with an under-
standing of the role of MRD in childhood T-ALL patients
especially in Chinese T-ALL population and treatment
protocols.
Conclusion
Our study showed that early treatment responses were
important predictors of outcome in childhood T-ALL
patients. Prednisone response was still one of the most
powerful predictive factors even in MRD based protocol.
Thus, traditional morphologic assessments of tumor
burden still play important roles in modern T-ALL treat-
ment protocols especially in underdeveloped countries.
Our study also demonstrated that MRD levels detected
by FCM at two time points were significantly independ-
ent prognostic factors and MRD based stratification was
superior to stratifications based on other conventional
risk factors.
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